(D)-PPA 1 

(D)-PPA 1 is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 serves as a potent PD-1/PD-L1 inhibitor. (D)-PPA 1 binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy^[1].

(D)-PPA 1 (0.2 mg/mL, 1.0 mg/mL) blocks the interaction between PD-1/PD-L1 at 1.0 mg/mL^[1].
(D)-PPA 1 (3.125-100 μM; 24 h, 48 h) doesn’t kill tumor cells directly with no affect on CT26 cells growth^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

(D)-PPA 1 (2 mg/kg; s.c. or i.p.; once daily for 7 d) inhibits CT26 tumor growth in vivo in mice^[1].
(D)-PPA 1 (40 μg/mouse in 200 μL; i.v.; single dose) has the ability to target to tumor tissue in CT26-tumor-bearing mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1555.65

C₇₀H₉₈N₂₀O₂₁

1620813-53-7

D-{Asn-Tyr-Ser-Lys-Pro-Thr-Asp-Arg-Gln-Tyr-His-Phe}

D-{NYSKPTDRQYHF}

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Chang HN, et al. Blocking of the PD-1/PD-L1 Interaction by a D-Peptide Antagonist for Cancer Immunotherapy. Angew Chem Int Ed Engl. 2015 Sep 28;54(40):11760-4.  [Content Brief]